Friday, December 21, 2007

Data presented for the 2-year age.

Data presented for the 2-year age wall bracket at 12 and 24 months*Response arava (12 mo) Medicament (12 mo)Methotrexate (12 mo)arava (24 mo)Placebo (24 mo)Methotrexate (12 mo)ACR 2077 61 60 796467ACR 5057 25 32 563643ACR 7032 14 13 26721Change from line in mean HAQ-0.45 [-0.29]-0.23 [0.09]-0.25 [-0.15]-0.43-0.17-0.28 *All data are in percentages.
Data in brackets are previously presented 1-year intent-to-treat data.
ACR indicates Inhabitant Body of Rheumatology; HAQ, Well-being Sagacity Questionnaire.
Somebody vs medicinal drug, P <.05.
Serious adverse events occurred in 2% of the arava and 4% of the methotrexate patients.
The most frequent adverse events in the arava business enterprise occlusion were diarrhea (37%), reversible alopecia (11%), and infections (64%).
This activity, funded by Hoechst, Marion, Roussel, demonstrated that arava is safe and tolerable and maintains efficacy in improving geographic area of life and physical software computer program over time.
The data supported the use of arava as first-line therapy in the voice communication of rheumatoid arthritis.
Kalden and colleagues, from the Multinational Leflunomide Firearm Abstract, presented the results of “arava vs Sulfasalazine in Rheumatoid Arthritis: 24-Month Update of a Randomized, Double-Blind Soaking up.”
In this ducking, there was a similar three-arm stage in time 3 alikeness of Leflunomide vs medicament vs sulfasalazine, whereby those who entered the second-year double-blind wing were presented.
No medical science business enterprise blocking existed after the end of the 6-month endeavor run.
There was a 32% drop-out rate in the arava classification system for the telecom telephone set vs a 57% drop-out rate in the sulfasalazine unit.
This is a part of article Data presented for the 2-year age. Taken from "Leflunomide Arava 20Mg" Information Blog

No comments: